Multiplex genome editing of mammalian cells for producing recombinant heparin
Bryan E. Thacker(Howard Hughes Medical Institute), Charles A. Glass(General Atomics (United States)), John Hogwood(National Institute for Biological Standards and Control), Zhenping Wang(University of California San Diego), Benjamin P. Kellman(Ragon Institute of MGH, MIT and Harvard), Susan T. Sharfstein(SUNY Polytechnic Institute), Jeeyoung Park(General Atomics (United States)), Anna Di Nardo(San Gallicano Hospital), Barbara Mulloy(Imperial College London), Annie Chea(General Atomics (United States)), Jeffrey D. Esko(University of California San Diego), Kristen Thorne(General Atomics (United States)), Jeanine M. Walenga(University of Rochester Medical Center), Nathan E. Lewis(University of Georgia), Kimberly Glass(Brigham and Women's Hospital), Elaine Gray(National Institute for Biological Standards and Control), Colin Cartwright(General Atomics (United States)), Walter Jeske(Loyola University Chicago)
Cited by 16
Related Papers
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
|Cell|1991|2.4k
Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0
|Nature Protocols|2011|1.9k
Heparan Sulfate Proteoglycans
|Cold Spring Harbor Perspectives in Biology|2011|1.5k
Deciphering cell–cell interactions and communication from gene expression
|Nature Reviews Genetics|2020|1.3k